Data / Drug companies / Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC: 41 products in the FDA NDC directory, labeler code 76045
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Fresenius Kabi USA, LLC (labeler code 76045) lists 41 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 41 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.
The request: Watch Fresenius Kabi USA, LLC (FDA labeler code 76045): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 76045
- Products in commercial distribution
- 41
- Packages
- 39
- Finished drugs by generic name
- 15
- Prescription products
- 41
- Over the counter products
- 0
- Controlled substance products
- Schedule II 9, Schedule IV 5
- Flagged as original packager
- 40 of 40 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- March 26, 2013
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 26 | 63.4% |
| New drug applications (NDA) | 15 | 36.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 41 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Morphine sulfate | 6 | 31 |
| Glycopyrrolate | 5 | 64 |
| Midazolam hydrochloride | 4 | 19 |
| Ketorolac tromethamine | 4 | 69 |
| Dexamethasone sodium phosphate | 4 | 25 |
| Hydromorphone hydrochloride | 3 | 20 |
| Metoclopramide hydrochloride | 2 | 13 |
| Ondansetron hydrochloride | 2 | 48 |
| Naloxone hydrochloride | 2 | 40 |
| Neostigmine methylsulfate | 2 | 24 |
| Rocuronium bromide | 2 | 25 |
| Diphenhydramine hydrochloride | 2 | 127 |
| Heparin sodium | 1 | 23 |
| Diazepam | 1 | 51 |
| Sugammadex | 1 | 22 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 37 | 90.2% |
| Injection | 2 | 4.9% |
| Injection, emulsion | 2 | 4.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex | 76045-219 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Diphenhydramine Hydrochloride | 76045-235 | Injection, solution | Generic drugs (ANDA) | June 2, 2025 |
| Naloxone Hydrochloride | 76045-114 | Injection, solution | Generic drugs (ANDA) | April 2, 2024 |
| Naloxone Hydrochloride | 76045-112 | Injection, solution | Generic drugs (ANDA) | April 2, 2024 |
| Dexamethasone Sodium Phosphate | 76045-212 | Injection, emulsion | Generic drugs (ANDA) | February 21, 2024 |
| Rocuronium | 76045-221 | Injection, solution | New drug applications (NDA) | October 11, 2023 |
| Rocuronium | 76045-220 | Injection, solution | New drug applications (NDA) | October 11, 2023 |
| Diazepam | 76045-204 | Injection, solution | Generic drugs (ANDA) | November 10, 2022 |
| Ondansetron | 76045-216 | Injection, solution | Generic drugs (ANDA) | May 31, 2022 |
| Glycopyrrolate | 76045-223 | Injection | New drug applications (NDA) | April 21, 2022 |
| Glycopyrrolate | 76045-023 | Injection | New drug applications (NDA) | April 21, 2022 |
| Midazolam | 76045-211 | Injection, solution | Generic drugs (ANDA) | April 16, 2021 |
| Dexamethasone Sodium Phosphate | 76045-210 | Injection, solution | Generic drugs (ANDA) | November 30, 2020 |
| Glycopyrrolate | 76045-208 | Injection, solution | Generic drugs (ANDA) | October 30, 2020 |
| Glycopyrrolate | 76045-206 | Injection, solution | Generic drugs (ANDA) | October 30, 2020 |
| Ketorolac Tromethamine | 76045-209 | Injection, solution | Generic drugs (ANDA) | September 1, 2020 |
| Dilaudid | 76045-009 | Injection, solution | New drug applications (NDA) | December 4, 2018 |
| Neostigmine Methylsulfate | 76045-383 | Injection, solution | New drug applications (NDA) | September 18, 2018 |
| Neostigmine Methylsulfate | 76045-214 | Injection, solution | New drug applications (NDA) | September 18, 2018 |
| Glycopyrrolate | 76045-203 | Injection, solution | Generic drugs (ANDA) | July 25, 2018 |
| Dexamethasone Sodium Phosphate | 76045-109 | Injection, emulsion | Generic drugs (ANDA) | July 6, 2018 |
| Dilaudid | 76045-121 | Injection, solution | New drug applications (NDA) | December 16, 2016 |
| Dilaudid | 76045-010 | Injection, solution | New drug applications (NDA) | December 16, 2016 |
| Heparin Sodium | 76045-108 | Injection, solution | Generic drugs (ANDA) | June 10, 2016 |
| Ondansetron | 76045-103 | Injection, solution | Generic drugs (ANDA) | December 10, 2015 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.